AP

Aptabio Therapeutics Inc.

Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.

293780 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 흥덕1로 13 타워동 에이504호(영덕동, 흥덕아이티밸리), 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptabio Therapeutics Inc. is a biopharmaceutical company specializing in the development of first-in-class drugs for intractable diseases. The company leverages two proprietary platform technologies to address high unmet medical needs. Its primary platform develops selective inhibitors of the NOX family of enzymes to control oxidative stress, targeting inflammation and fibrosis-related conditions like diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform focuses on modulating Cancer-Associated Fibroblasts (CAF) to enhance the efficacy of immune-oncology therapies and overcome treatment resistance in hard-to-treat cancers.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Aptabio Therapeutics Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-28 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (ABF101의 미국 FDA 제1상 임상시험계획 승인신청(IND…
Korean 13.7 KB

Automate Your Workflow. Get a real-time feed of all Aptabio Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Aptabio Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden KARO
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea 038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea 256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan 4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland KNRS
KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan 4547
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden KLAR

Talk to a Data Expert

Have a question? We'll get back to you promptly.